Phaseline

Targets › CBL

CBL (E3 ubiquitin-protein ligase CBL): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2026.

E3 ubiquitin-protein ligase that acts as a negative regulator of many signaling pathways by mediating ubiquitination of cell surface receptors. Accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then transfers it to substrates promoting their degradation by the proteasome. (UniProt, P22681)

Open in Phaseline: the race on CBL, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
HotSpot TherapeuticsHST-1011
CBL-B inhibitor
CBLPhase 1Solid Tumor, AdultDec 2026

Conditions

Solid Tumor, Adult (1)

Modalities

mixed (1)

Companies

HotSpot Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.